Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The limited documentation surrounding CIDP is primarily due to its relatively low prevalence and the complex nature of its clinical presentation. As a rare condition, CIDP affects fewer individuals, resulting in fewer systematic studies and clinical trials. Additionally, the variability in symptoms and progression among patients complicates the establishment of a comprehensive clinical profile.
To navigate your care effectively, seek a neurologist with expertise in inflammatory neuropathies or CIDP specifically. This specialist can provide tailored management strategies. Additionally, consider exploring resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for information and support. Participating in clinical trials may also be beneficial; check the active trials listed on ClinicalTrials.gov for opportunities that align with your condition.
There are currently 57 active clinical trials investigating various aspects of CIDP, reflecting ongoing research efforts to better understand and treat the condition. Notable orphan drugs in development include nipocalimab, a recombinant humanized IgG4 monoclonal antibody targeting the pHERV-W Envelope protein, and a recombinant multimerized human IgG1 Fc. For more information on active trials, visit ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=polyneuropathy%2C%20inflammatory%20demyelinating%2C%20chronic.
Actionable guidance for navigating care for polyneuropathy, inflammatory demyelinating, chronic
To navigate your care effectively, seek a neurologist with expertise in inflammatory neuropathies or CIDP specifically. This specialist can provide tailored management strategies. Additionally, consider exploring resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for information and support. Participating in clinical trials may also be beneficial; check the active trials listed on ClinicalTrials.gov for opportunities that align with your condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 6 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning polyneuropathy, inflammatory demyelinating, chronic
Updated Feb 13, 2026
A case report details an 89-year-old man with chronic inflammatory demyelinating polyradiculoneuropathy who developed encephalitis caused by human herpesvirus 6 variant A while on prednisolone. This highlights potential complications in elderly patients with underlying neurological conditions.
A personal story highlights how a diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) motivated the author to engage in advocacy efforts. The narrative emphasizes the importance of community support and awareness for rare diseases.
A personal story highlights the resilience of individuals diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as they strive to pursue their dreams despite the challenges posed by the disease. This narrative emphasizes the importance of community support and advocacy for rare disease awareness.